查看購物車
  • Simplified Chinese
  • English
  • Japanese
全球GLP-1促效劑市場按產品、分子、類型、適應症、劑型、給藥途徑、最終用戶和地區分類－預測至2033年
市場調查報告書
商品編碼
1859656

全球GLP-1促效劑市場按產品、分子、類型、適應症、劑型、給藥途徑、最終用戶和地區分類－預測至2033年

GLP-1 Agonists Market by Product (Ozempic, Wegovy, Mounjaro), Molecule (semaglutide, tirzepatide), Type (Patented, Biosimilars), Format (Single dose, Multi-dose, Tablets), ROA (SC, Oral), Indication (Diabetes, Obesity) - Global Forecast to 2033
出版日期: | 出版商: MarketsandMarkets | 英文 456 Pages | 訂單完成後即時交付

價格

GLP-1促效劑市場預計將從2025年的644.2億美元成長到2033年的1,707.5億美元，預測期內複合年成長率為13.0%。

由於幾個關鍵促進因素，GLP-1促效劑市場正在快速擴張。其中一個顯著因素是監管機構批准的GLP-1藥物新核准數量不斷增加。這些核准擴大了GLP-1促效劑的使用範圍，使其能夠治療更廣泛的患者群體，包括心血管疾病、阿茲海默症、阻塞型睡眠呼吸中止症和肥胖症等新適應症。

調查範圍
調查年度 2024-2033
基準年 2024
預測期 2025-2033
考慮單位 金額（十億美元）
部分 按產品、分子、類型、適應症、劑型、給藥途徑、最終用戶和地區
目標區域 北美、歐洲、亞太地區、拉丁美洲、中東和非洲

全球糖尿病和肥胖症盛行率的不斷上升進一步推動了市場的強勁成長，因為越來越多的患者需要針對這些慢性疾病的有效治療方法。同時，GLP-1促效劑因其在改善血糖控制和顯著減輕體重等方面展現出的臨床益處，正被越來越多的醫療保健提供者所接受。

GLP-1激動劑市場-IMG1

依類型分類，GLP-1促效劑市場可分為專利產品及生物相似藥。專利產品將在2024年佔據最大的市場佔有率。預計從2026年起，生物相似藥的使用率將有所提高，目前專利產品仍佔據市場主導地位。然而，隨著司美Semaglutide的專利在2026年後到期，生物相似藥市場預計將在此之後迎來顯著成長。取得專利的GLP-1促效劑之所以在處方模式中佔據主導地位，是因為其擁有強大的臨床數據、良好的安全性以及大量的市場投入。此外，原廠GLP-1受體激動劑製造商已建立了廣泛的健保覆蓋範圍，確保患者即使面臨高昂的藥價也能獲得治療。這些因素預計將推動市場成長。

根據最終用戶，GLP-1促效劑市場可細分為居家照護機構和健身/體重管理中心、長期護理機構以及醫院和專科診所。到了2024年，家庭護理機構和健身/體重管理中心細分市場佔據GLP-1促效劑市場的最大佔有率。此細分市場佔有率較大的原因在於患者需求的不斷變化以及肥胖和糖尿病管理的整體趨勢，尤其是大多數GLP-1藥物都有皮下或口服製劑，方便給藥。這提高了患者的依從性，許多患者更傾向於自行給藥，尤其是在針對肥胖和第2型糖尿病的長期治療中。肥胖症的快速成長和預防醫學的普及也使得GLP-1在家庭環境中的應用更加普遍，從而推動了該細分市場佔有率的成長。

2024年，由於人口結構、醫療保健、監管和商業性因素的共同作用，美國在GLP-1促效劑市場中佔據主導地位。美國是全球肥胖症和第2型糖尿病盛行率最高的國家之一，這顯著擴大了符合GLP-1療法適用條件的患者族群。先進的醫療保健基礎設施和醫生較高的認知度確保了新治療方法的快速普及，而強大的保險覆蓋和報銷機制則使更多患者能夠獲得治療。

本報告考察了全球 GLP-1促效劑市場，並按產品、分子、類型、適應症、劑型、給藥途徑、最終用戶、區域趨勢和公司概況對市場進行了全面分析。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章重要考察

  • 全球GLP-1促效劑市場概述
  • 北美：GLP-1促效劑市場（按適應症和國家分類），2024年
  • 2024年GLP-1促效劑市場按劑型分類
  • 2024年GLP-1促效劑市場（依最終用戶分類）
  • GLP-1促效劑市場：地域成長機會
  • 未滿足的需求和閒置頻段
  • 成長機會的策略分析
  • 新的經營模式和生態系統變化
  • 相互關聯的市場與跨產業機遇
  • GLP-1促效劑生產能力亮點
  • 2025年至2033年主要藥品上市預測
  • 永續性影響和監管政策舉措

第5章 市場概覽

  • 介紹
  • 市場動態
  • 影響客戶業務的趨勢/顛覆性因素
  • 定價分析
  • 產業趨勢
  • 技術分析
  • 管道分析
  • 技術/產品藍圖
  • 價值鏈分析
  • 生態系分析
  • 波特五力分析
  • 監管分析
  • 2025-2026 年主要會議和活動
  • 客戶狀況與購買行為
  • 投資/資金籌措方案
  • 救贖方案
  • 人工智慧/人工智慧生成對GLP-1促效劑市場的影響
  • 2025年川普關稅對GLP-1促效劑市場的影響

6. GLP-1促效劑市場（依產品分類）

  • 介紹
  • GLP-1促效劑的預期市場規模
  • 奧森皮克
  • Trulicity
  • 蒙加羅
  • 韋戈比
  • 呂伯圖斯
  • Zepbound
  • 奧福格列酮
  • 卡格里塞馬
  • 沙博杜胜肽
  • 瑞他托肽
  • Semaglutide生物相似藥
  • 其他GLP-1生物類似藥
  • 其他產品

7. GLP-1促效劑市場（依分子類型分類）

  • 介紹
  • Semaglutide
  • Tirzepatide
  • Dulaglutide
  • 卡格列肽和Semaglutide的聯合用藥
  • 奧福格列酮
  • 沙博杜胜肽
  • 瑞他托肽
  • 其他

8. GLP-1促效劑市場（按類型）

  • 介紹
  • 專利產品
  • 生物相似藥

9. GLP-1促效劑市場（依適應症分類）

  • 介紹
  • 糖尿病
  • 肥胖
  • 其他

第10章 GLP-1促效劑市場（依劑型分類）

  • 介紹
  • 單劑量規格
  • 多劑量規格
  • 自動噴射器

11. GLP-1促效劑市場（依給藥途徑）

  • 介紹
  • 皮下注射
  • 口服

12. 依最終用戶分類的 GLP-1促效劑市場

  • 介紹
  • 居家照護設施和健身/體重管理設施
  • 長期照護機構
  • 醫院和專科診所

13. 依地區分類的GLP-1促效劑市場

  • 介紹
  • 北美洲
    • 北美宏觀經濟展望
    • 美國
    • 加拿大
  • 歐洲
    • 歐洲宏觀經濟展望
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 其他
  • 亞太地區
    • 亞太宏觀經濟展望
    • 中國
    • 日本
    • 印度
    • 澳洲
    • 韓國
    • 其他
  • 拉丁美洲
    • 拉丁美洲宏觀經濟展望
    • 巴西
    • 墨西哥
    • 其他
  • 中東
    • 中東宏觀經濟展望
    • 海灣合作理事會國家
    • 其他
  • 非洲
    • 醫療保健和生命科學產業的成長
    • 非洲宏觀經濟展望

第14章 競爭格局

  • 介紹
  • 關鍵策略/優勢
  • 2020-2024年收入分析
  • 2024年市佔率分析
  • 公司估值矩陣：主要參與企業，2024 年
  • 公司估值矩陣：主要企業（含研發線產品），2024 年
  • 公司估值矩陣：Start-Ups/中小企業，2024 年
  • 估值和財務指標
  • 品牌/產品對比
  • 競爭場景

第15章 公司簡介

  • 介紹
  • 主要參與企業
    • NOVO NORDISK A/S
    • ELI LILLY AND COMPANY
    • SANOFI
    • HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED
    • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • INNOVENT
    • PEGBIO CO., LTD.
    • SCIWIND BIOSCIENCES CO., LTD.
    • ZEALAND PHARMA
    • STRUCTURE THERAPEUTICS, INC.
    • VIKING THERAPEUTICS
    • SUN PHARMACEUTICAL INDUSTRIES LTD.
    • VTV THERAPEUTICS
    • ALTIMMUNE
    • AMGEN INC.
    • GLENMARK PHARMACEUTICALS LTD.
    • BIOCON
    • TEVA PHARMACEUTICAL INDUSTRIES LTD.
    • F. HOFFMANN-LA ROCHE LTD.
  • 其他公司
    • TERNS PHARMACEUTICALS, INC.
    • METAVIA
    • SCOHIA PHARMA, INC.
    • REGOR THERAPEUTICS GROUP
    • NEURALY INC.
    • I2O THERAPEUTICS, INC.
    • PFIZER INC.
    • HANMI PHARM CO.,LTD.
    • JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.
    • BIOMED INDUSTRIES, INC.

第16章附錄

Product Code: PH 9080

The GLP-1 agonists market is expected to reach USD 170.75 billion in 2033 from USD 64.42 billion in 2025 at a CAGR of 13.0% during the forecast period. The GLP-1 agonists market has expanded rapidly due to several key drivers. One prominent factor is the growing number of new indication approvals for GLP-1 drugs by regulatory agencies. These approvals extend the uses of GLP-1 agonists beyond initial indications, allowing for treatments in broader patient populations, including newer indications such as cardiovascular conditions, Alzheimer's disease, obstructive sleep apnea, and obesity.

Scope of the Report
Years Considered for the Study2024-2033
Base Year2024
Forecast Period2025-2033
Units ConsideredValue (USD billion)
SegmentsProduct, Molecule, Type, Format, Route of administration, Indication, End user
Regions coveredNorth America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa

The rising prevalence of these chronic conditions globally further supports strong market growth, as more patients require effective therapies for diabetes and obesity. In parallel, GLP-1 agonists offer proven clinical benefits such as improved glycemic control and significant weight reduction, increasing their adoption rates among healthcare providers.

GLP-1 Agonists Market - IMG1

The patented products segment accounted for the largest share of the GLP-1 agonists market by type in 2024.

Based on type, the GLP-1 agonists market is segmented into patented products and biosimilars. In 2024, the patented products accounted for the largest share of the market. As biosimilars are expected to gain adoption post-2026, patented products currently account for the complete market. However, with the semaglutide patent expiring in 2026 onwards, the market for biosimilars is expected to grow significantly thereafter. Patented GLP-1 agonists dominate prescribing patterns due to their robust clinical data, extensive safety profiles, and premium marketing investments. Additionally, the original GLP-1 makers have established broad insurance coverage, ensuring patient access despite high list prices. These factors are expected to support market growth.

By end user, the home-care settings and fitness/ weight management facilities accounted for the largest share in the GLP-1 agonists market in 2024.

Based on end user, the GLP-1 agonists market is segmented into home-care settings and fitness/ weight management facilities, long-term care facilities, and hospitals & specialty clinics. In 2024, the home-care settings and fitness/weight management facilities segment accounted for the largest share of the GLP-1 agonists market. The large share of this end-user segment can be attributed to the evolving patient needs and broader trends in obesity and diabetes management. Home care settings offer convenience and flexible dosing schedules for patients, especially as most GLP-1 therapies are available in easy-to-administer, subcutaneous or oral formats. This increases patient adherence, with many preferring to self-administer medications, particularly for long-term therapies targeting obesity and type 2 diabetes. The spike in obesity prevalence and the mainstreaming of preventive health have also made GLP-1 usage in home environments much more common, driving share growth in this segment.

The US dominated the GLP-1 agonists market in 2024.

In 2024, the US dominated the GLP-1 agonists market due to a convergence of demographic, healthcare, regulatory, and commercial factors. The US has one of the highest prevalence rates globally for both obesity and type 2 diabetes, which significantly expands the patient pool eligible for GLP-1 treatment. Advanced healthcare infrastructure and widespread physician awareness ensure swift adoption of new therapies, while robust insurance coverage and reimbursement help broad patient access.

The primary interviews conducted for this report can be categorized as follows:

  • By Respondent: Supply-side- 70% and Demand-side 30%
  • By Designation: Managers - 45%, CXOs & Directors - 30%, and Executives - 25%
  • By Region: North America - 40%, Europe -25%, Asia Pacific -25%, Latin America -5% and the Middle East & Africa- 5%

List of Companies Profiled in the Report:

  • Novo Nordisk A/S (Denmark)
  • Eli Lilly and Company (US)
  • Sanofi (France)
  • Hansoh Pharmaceutical Group Co., Ltd. (China)
  • Boehringer Ingelheim International GmbH (Germany)
  • Innovent (China)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Pegbio Co. Ltd (China)
  • Structure Therapeutics (US)
  • Viking Therapeutics (US)
  • Amgen Inc. (Switzerland)
  • Altimmune (US)
  • Glenmark (India)
  • Biocon (India)
  • Teva Pharmaceuticals (Israel)
  • Terns Pharmaceuticals, Inc. (US)
  • VTV Therapeutics (US)
  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Hanmi Pharm Co., Ltd. (South Korea)
  • Jiangsu Hengrui Pharmaceuticals Co., Ltd. (China)
  • Pfizer Inc. (US)
  • MetaVia Inc (US)
  • SCOHIA PHARMA, Inc. (Japan)
  • Sciwind Biosciences Co., Ltd. (China)
  • i2o Therapeutics, Inc. (US)
  • Biomed Industries, Inc. (US)
  • Neuraly Inc. (US)

Research Coverage

This research report categorizes the GLP-1 agonists market by product (ozempic, wegovy, mounjaro, zepbound, rybelsus, trulicity, orforglipron, cagrisema, survodutide, retatrutide, semaglutide biosimilars, other GLP-1 biosimilars, other products), molecule (Semaglutide, Tirzepatide, Dulaglutide, Cagrilintide semaglutide combination, Orforglipron, Survodutide, Retatrutide, Other molecules), type (patented, biosimilars), format (single-dose, multi-dose, tablets), indication (diabetes, obesity, other indications), route of administration (subcutaneous, oral), end user (home-care settings and fitness/ weight management facilities, long-term care facilities, and hospitals and specialty clinics) and region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa). The report's scope covers detailed information regarding the leading factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the GLP-1 agonists market. A thorough analysis of the key industry players has provided insights into their business overview, products offered, key strategies, collaborations, partnerships, and agreements. Product launches & approvals, expansions, acquisitions, partnerships, product pipelines, collaborations, and agreements are the recent developments associated with the GLP-1 agonists market.

Key Benefits of Buying the Report

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall GLP-1 agonists market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business better and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

  • Analysis of key drivers (expanding manufacturing capacity, shift of GLP-1 drugs from diabetes specialty to broader treatment option, growing prevalence of obesity and type 2 diabetes), restraints (stringent cost and payer controls), opportunities (increasing studies on oral GLP-1), and challenges (counterfeits and compounded GLP-1 gray market, safety, tolerability, persistence issues) influencing the growth of the market.
  • Product Development/Innovation: Detailed insights on newly approved and launched products of the GLP-1 agonists market
  • Market Development: Comprehensive information about lucrative markets - the report analyzes the market across varied regions.
  • Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the GLP-1 agonists market
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of key players, including Novo Nordisk (Denmark), Eli Lilly (US), and Sanofi (France), among other players. A detailed analysis of the key industry players has been conducted to provide insights into their key strategies, product approvals and launches, acquisitions, partnerships, agreements, collaborations, expansions, recent developments, investment and funding activities, brand/product comparative analysis, and vendor valuation and financial metrics of the GLP-1 agonists market.

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
    • 1.3.4 CURRENCY CONSIDERED
  • 1.4 STAKEHOLDERS
  • 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

  • 2.1 RESEARCH DATA
    • 2.1.1 SECONDARY DATA
      • 2.1.1.1 Key objectives of secondary research
    • 2.1.2 PRIMARY DATA
      • 2.1.2.1 Breakdown of primaries
      • 2.1.2.2 Key objectives of primary research
  • 2.2 MARKET SIZE ESTIMATION
    • 2.2.1 REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH)
    • 2.2.2 SECONDARY DATA & PRIMARY INTERVIEWS
    • 2.2.3 SEGMENTAL MARKET SIZE ASSESSMENT
  • 2.3 MARKET GROWTH FORECAST
  • 2.4 DATA TRIANGULATION
  • 2.5 STUDY ASSUMPTIONS
  • 2.6 RISK ANALYSIS

3 EXECUTIVE SUMMARY

  • 3.1 KEY INSIGHTS & MARKET HIGHLIGHTS
  • 3.2 STRATEGIC IMPERATIVES FOR STAKEHOLDERS
  • 3.3 DISRUPTIVE TRENDS SHAPING GLP-1 AGONISTS MARKET
  • 3.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS

4 PREMIUM INSIGHTS

  • 4.1 GLOBAL GLP-1 AGONISTS MARKET SNAPSHOT
  • 4.2 NORTH AMERICA: GLP-1 AGONISTS MARKET, BY INDICATION AND COUNTRY, 2024
  • 4.3 GLP-1 AGONISTS MARKET, BY FORMAT, 2024
  • 4.4 GLP-1 AGONISTS MARKET, BY END USER, 2024
  • 4.5 GLP-1 AGONISTS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
  • 4.6 UNMET NEEDS & WHITE SPACES
  • 4.7 STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES
    • 4.7.1 STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES
  • 4.8 EMERGING BUSINESS MODELS & ECOSYSTEM SHIFTS
  • 4.9 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
  • 4.10 GLP-1 AGONISTS PRODUCTION CAPACITY HIGHLIGHTS
  • 4.11 KEY DRUG LAUNCHES EXPECTED, 2025-2033
  • 4.12 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES

5 MARKET OVERVIEW

  • 5.1 INTRODUCTION
  • 5.2 MARKET DYNAMICS
    • 5.2.1 DRIVERS
      • 5.2.1.1 Expanding manufacturing capacities of large pharmaceutical companies
      • 5.2.1.2 Shift of GLP-1 drugs from diabetes specialty to broader treatment options
      • 5.2.1.3 Rising prevalence of obesity and type-2 diabetes
    • 5.2.2 RESTRAINTS
      • 5.2.2.1 Stringent cost and payer controls
    • 5.2.3 OPPORTUNITIES
      • 5.2.3.1 Increasing studies on oral GLP-1
    • 5.2.4 CHALLENGES
      • 5.2.4.1 Counterfeits and compounded GLP-1 gray market
      • 5.2.4.2 Safety, tolerability, and persistence issues
  • 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
    • 5.3.1 KEY GLP-1 AGONISTS PIPELINE & EXPECTED LAUNCHES
  • 5.4 PRICING ANALYSIS
    • 5.4.1 AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY KEY PLAYER, 2022-2024
    • 5.4.2 AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY KEY PLAYER, 2022-2024
    • 5.4.3 AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY REGION, 2022-2024
    • 5.4.4 FACTORS IMPACTING GLP-1 AGONISTS PRICING
  • 5.5 INDUSTRY TRENDS
    • 5.5.1 SHIFT OF WEEKLY INJECTABLES TOWARD ORALS AND MULTI-AGONISTS
    • 5.5.2 VERTICAL INTEGRATION AND CAPACITY SCALE-UP TO MEET DEMAND
  • 5.6 TECHNOLOGY ANALYSIS
    • 5.6.1 KEY TECHNOLOGIES
      • 5.6.1.1 Chemical synthesis
      • 5.6.1.2 Recombinant DNA technology
    • 5.6.2 COMPLEMENTARY TECHNOLOGIES
      • 5.6.2.1 Peptelligence
      • 5.6.2.2 PEGylation and polymer encapsulation
    • 5.6.3 ADJACENT TECHNOLOGIES
      • 5.6.3.1 Hydrogel depot technologies
      • 5.6.3.2 Technologies for oral delivery of GLP-1 analogues
  • 5.7 PIPELINE ANALYSIS
  • 5.8 TECHNOLOGY/PRODUCT ROADMAP
  • 5.9 VALUE CHAIN ANALYSIS
  • 5.10 ECOSYSTEM ANALYSIS
    • 5.10.1 ROLE IN ECOSYSTEM
  • 5.11 PORTER'S FIVE FORCES ANALYSIS
    • 5.11.1 THREAT OF NEW ENTRANTS
    • 5.11.2 THREAT OF SUBSTITUTES
    • 5.11.3 BARGAINING POWER OF SUPPLIERS
    • 5.11.4 BARGAINING POWER OF BUYERS
    • 5.11.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.12 REGULATORY ANALYSIS
    • 5.12.1 REGULATORY LANDSCAPE
    • 5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.13 KEY CONFERENCES & EVENTS, 2025-2026
  • 5.14 CUSTOMER LANDSCAPE & BUYER BEHAVIOR
    • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 5.14.2 KEY BUYING CRITERIA
    • 5.14.3 ADOPTION BARRIER & INTERNAL FRICTION
  • 5.15 INVESTMENT/FUNDING SCENARIO
  • 5.16 REIMBURSEMENT SCENARIO
  • 5.17 IMPACT OF AI/GEN AI ON GLP-1 AGONISTS MARKET
    • 5.17.1 IMPACT AT DEVELOPMENT AND MANUFACTURING STAGES
    • 5.17.2 AI USE CASES
    • 5.17.3 KEY COMPANIES IMPLEMENTING AI
    • 5.17.4 FUTURE OF AI/GEN AI IN GLP-1 AGONIST DRUG DEVELOPMENT ECOSYSTEM
  • 5.18 IMPACT OF 2025 TRUMP TARIFF ON GLP-1 AGONISTS MARKET
    • 5.18.1 INTRODUCTION
    • 5.18.2 KEY TARIFF RATES
    • 5.18.3 PRICE IMPACT ANALYSIS
    • 5.18.4 IMPACT ON REGION
      • 5.18.4.1 North America
      • 5.18.4.2 Europe
      • 5.18.4.3 Asia Pacific
    • 5.18.5 IMPACT ON END-USE INDUSTRIES
      • 5.18.5.1 Hospitals & specialty centers
      • 5.18.5.2 Long-term care facilities

6 GLP-1 AGONISTS MARKET, BY PRODUCT

  • 6.1 INTRODUCTION
  • 6.2 GLP-1 AGONISTS VOLUME MARKET ESTIMATION
  • 6.3 OZEMPIC
    • 6.3.1 ANTICIPATED PATENT EXPIRY OF SEMAGLUTIDE STARTING IN 2026 AND EXPECTED NEW DRUG LAUNCHES TO NEGATIVELY IMPACT MARKET
  • 6.4 TRULICITY
    • 6.4.1 LOSS OF PATENT EXCLUSIVITY AND HIGH COMPETITIVE PRESSURE TO DISRUPT MARKET GROWTH
  • 6.5 MOUNJARO
    • 6.5.1 DUAL MECHANISM AS BOTH GIP AND GLP-1 RECEPTOR AGONIST TO PROPEL ADOPTION
  • 6.6 WEGOVY
    • 6.6.1 INCREASING USE FOR WEIGHT MANAGEMENT TO SUPPORT MARKET GROWTH
  • 6.7 RYBELSUS
    • 6.7.1 EASE OF ADMINISTRATION TO FUEL ADOPTION AMONG PATIENTS
  • 6.8 ZEPBOUND
    • 6.8.1 INCREASED FOCUS ON OBESITY MANAGEMENT TO INDICATE HUGE GROWTH POTENTIAL
  • 6.9 ORFORGLIPRON
    • 6.9.1 ORFORGLIPRON TO GAIN HIGH POTENTIAL DUE TO DEVICE-FREE LOGISTICS AND NO FASTING WINDOW
  • 6.10 CAGRISEMA
    • 6.10.1 FOCUS ON CHRONIC WEIGHT MANAGEMENT AND TYPE 2 DIABETES TREATMENT TO SPUR MARKET GROWTH
  • 6.11 SURVODUTIDE
    • 6.11.1 STRONG CLINICAL EFFICACY IN OBESITY AND METABOLIC DISEASE MANAGEMENT TO AID MARKET GROWTH
  • 6.12 RETATRUTIDE
    • 6.12.1 STRONG WEIGHT-LOSS SIGNALS IN PHASE-2 DIABETES AND GLOBAL PHASE-3 CLINICAL PIPELINE TO DRIVE MARKET
  • 6.13 SEMAGLUTIDE BIOSIMILARS
    • 6.13.1 HIGH DEMAND FOR AFFORDABLE DIABETES AND OBESITY TREATMENTS TO AID GROWTH
  • 6.14 OTHER GLP-1 BIOSIMILARS
  • 6.15 OTHER PRODUCTS

7 GLP-1 AGONISTS MARKET, BY MOLECULE

  • 7.1 INTRODUCTION
  • 7.2 SEMAGLUTIDE
    • 7.2.1 PROVEN EFFICACY IN SIGNIFICANT WEIGHT LOSS AND GLYCEMIC CONTROL TO SUPPORT GROWTH
  • 7.3 TIRZEPATIDE
    • 7.3.1 STRONG EFFECTIVENESS IN OBESITY TREATMENT TO ENHANCE PHYSICIAN CONFIDENCE AND PAYER INTEREST
  • 7.4 DULAGLUTIDE
    • 7.4.1 USAGE IN PEDIATRIC TYPE 2 DIABETES FOR PATIENTS OVER 10 YEARS OLD TO ENHANCE USAGE IN SPECIALTY SETTINGS
  • 7.5 CAGRILINTIDE SEMAGLUTIDE COMBINATION
    • 7.5.1 SIGNIFICANT CLINICAL OUTCOMES IN WEIGHT MANAGEMENT TO DRIVE MARKET GROWTH
  • 7.6 ORFORGLIPRON
    • 7.6.1 NEEDLE-FREE ALTERNATIVE TO INCREASE CONVENIENCE AND SUPPORT ADOPTION AMONG PATIENTS
  • 7.7 SURVODUTIDE
    • 7.7.1 DUAL GCG/GLP-1 RECEPTOR AGONISM AND FAVORABLE CLINICAL EVIDENCE TO AID GROWTH
  • 7.8 RETATRUTIDE
    • 7.8.1 TRIPLE-AGONIST APPROACH AND BEST-IN-CLASS WEIGHT MANAGEMENT FOR OBESITY TO SHOW HIGH GROWTH POTENTIAL
  • 7.9 OTHER MOLECULES

8 GLP-1 AGONISTS MARKET, BY TYPE

  • 8.1 INTRODUCTION
  • 8.2 PATENTED PRODUCTS
    • 8.2.1 PATENTED GLP-1 BRANDS TO SHIFT FROM WEIGHT LOSS DRUGS TO CARDIOMETABOLIC THERAPIES FOR BETTER ACCESS AND DURABILITY
  • 8.3 BIOSIMILARS
    • 8.3.1 SEMAGLUTIDE BIOSIMILARS
      • 8.3.1.1 Upcoming patent expiry for major drugs in key markets to increase biosimilar adoption
    • 8.3.2 OTHER BIOSIMILARS

9 GLP-1 AGONISTS MARKET, BY INDICATION

  • 9.1 INTRODUCTIONS
  • 9.2 DIABETES
    • 9.2.1 HIGH DIABETES PREVALENCE TO FUEL MARKET ADOPTION
  • 9.3 OBESITY
    • 9.3.1 STRONG PIPELINE OF ANTI-OBESITY GLP-1 DRUGS TO DRIVE MARKET
  • 9.4 OTHER INDICATIONS

10 GLP-1 AGONISTS MARKET, BY FORMAT

  • 10.1 INTRODUCTION
  • 10.2 SINGLE-DOSE FORMATS
    • 10.2.1 EASE OF ADMINISTRATION, DOSING AMOUNT PRECISION, AND LOW CONTAMINATION RISK TO SUPPORT MARKET GROWTH
  • 10.3 MULTI-DOSE FORMATS
    • 10.3.1 COST-EFFECTIVENESS AND LOW MEDICAL WASTE GENERATION TO AUGMENT ADOPTION IN HEALTHCARE SETTINGS
  • 10.4 AUTOINJECTORS
    • 10.4.1 SIMPLIFIED INJECTION PROCESS WITH LOWER HUMAN ERRORS TO SUPPORT ADOPTION

11 GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION

  • 11.1 INTRODUCTION
  • 11.2 SUBCUTANEOUS ADMINISTRATION
    • 11.2.1 PEN INJECTORS
      • 11.2.1.1 Easy monitoring of volume and dosage strength to support adoption
    • 11.2.2 AUTOINJECTORS
      • 11.2.2.1 Simplified injection process with lower human errors to support adoption
  • 11.3 ORAL ADMINISTRATION
    • 11.3.1 ELIMINATION OF NEEDLEPHOBIA AND EASE OF USE TO DRIVE COMPLIANCE

12 GLP-1 AGONISTS MARKET, BY END USER

  • 12.1 INTRODUCTION
  • 12.2 HOME CARE SETTINGS AND FITNESS/ WEIGHT MANAGEMENT FACILITIES
    • 12.2.1 RISING NUMBER OF TELEHEALTH COMPANIES AND CONVENIENCE OF HOME CARE TO SUPPORT MARKET GROWTH
  • 12.3 LONG-TERM CARE FACILITIES
    • 12.3.1 GROWING GERIATRIC POPULATION WITH CHRONIC DISEASES TO SUPPORT SEGMENT GROWTH
  • 12.4 HOSPITALS & SPECIALTY CLINICS
    • 12.4.1 ORGANIZED ENVIRONMENT, PROFESSIONAL OVERSIGHT, AND ABILITY TO HANDLE COMPLEX PATIENT NEEDS TO DRIVE MARKET

13 GLP-1 AGONISTS MARKET, BY REGION

  • 13.1 INTRODUCTION
  • 13.2 NORTH AMERICA
    • 13.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
    • 13.2.2 US
      • 13.2.2.1 US to dominate North American GLP-1 agonists market during forecast period
    • 13.2.3 CANADA
      • 13.2.3.1 Favorable funding scenario and presence of strong research infrastructure to support market growth
  • 13.3 EUROPE
    • 13.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
    • 13.3.2 GERMANY
      • 13.3.2.1 Expertise in biotechnology and reputation as leading pharmaceutical manufacturing hub to expedite market growth
    • 13.3.3 UK
      • 13.3.3.1 Growing R&D initiatives for development of GLP-1 agonists drugs to support market growth
    • 13.3.4 FRANCE
      • 13.3.4.1 Favorable regulatory scenario and strong research infrastructure to propel market growth
    • 13.3.5 ITALY
      • 13.3.5.1 Presence of key pharmaceutical & biotechnology companies to boost market growth
    • 13.3.6 SPAIN
      • 13.3.6.1 High incidence of diabetes and obesity to augment market adoption of GLP-1 therapeutic drugs
    • 13.3.7 NETHERLANDS
      • 13.3.7.1 Strong focus on pharmaceutical R&D to support market growth
    • 13.3.8 REST OF EUROPE
  • 13.4 ASIA PACIFIC
    • 13.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
    • 13.4.2 CHINA
      • 13.4.2.1 Increasing endorsements of anti-obesity drugs by celebrities to drive market adoption
    • 13.4.3 JAPAN
      • 13.4.3.1 High diabetic population and favorable regulatory scenario to aid market growth
    • 13.4.4 INDIA
      • 13.4.4.1 Growing demand for cost-effective and accessible anti-obesity medications to aid market growth
    • 13.4.5 AUSTRALIA
      • 13.4.5.1 Significant government investment in obesity prevention to fuel market growth
    • 13.4.6 SOUTH KOREA
      • 13.4.6.1 Increasing strategic collaborations in obesity drugs to propel market growth
    • 13.4.7 REST OF ASIA PACIFIC
  • 13.5 LATIN AMERICA
    • 13.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
    • 13.5.2 BRAZIL
      • 13.5.2.1 Increasing partnerships with global pharmaceutical companies and rising diabetes cases to drive Brazilian market
    • 13.5.3 MEXICO
      • 13.5.3.1 Growing diabetes and obesity prevalence to support market growth
    • 13.5.4 REST OF LATIN AMERICA
  • 13.6 MIDDLE EAST
    • 13.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
    • 13.6.2 GCC COUNTRIES
      • 13.6.2.1 Kingdom of Saudi Arabia
        • 13.6.2.1.1 Pricing oversight of Saudi Food and Drug Authority and strong sales from leading industry players to drive market
      • 13.6.2.2 UAE
        • 13.6.2.2.1 Growing regulatory approvals for GLP-1 drugs to spur market growth
      • 13.6.2.3 Rest of GCC Countries
    • 13.6.3 REST OF MIDDLE EAST
  • 13.7 AFRICA
    • 13.7.1 GROWING HEALTHCARE AND LIFE SCIENCE INDUSTRY TO SUPPORT GROWTH
    • 13.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

14 COMPETITIVE LANDSCAPE

  • 14.1 INTRODUCTION
  • 14.2 KEY STRATEGIES/RIGHT TO WIN
    • 14.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN GLP-1 AGONISTS MARKET
  • 14.3 REVENUE ANALYSIS, 2020-2024
  • 14.4 MARKET SHARE ANALYSIS, 2024
  • 14.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
    • 14.5.1 STARS
    • 14.5.2 EMERGING LEADERS
    • 14.5.3 PERVASIVE PLAYERS
    • 14.5.4 PARTICIPANTS
  • 14.6 COMPANY EVALUATION MATRIX: KEY PLAYERS (WITH PRODUCTS IN PIPELINE), 2024
    • 14.6.1 STARS
    • 14.6.2 EMERGING LEADERS
    • 14.6.3 PERVASIVE PLAYERS
    • 14.6.4 PARTICIPANTS
    • 14.6.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
      • 14.6.5.1 Company footprint
      • 14.6.5.2 Region footprint
      • 14.6.5.3 Format footprint
      • 14.6.5.4 Route of administration footprint
      • 14.6.5.5 Indication footprint
  • 14.7 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
    • 14.7.1 PROGRESSIVE COMPANIES
    • 14.7.2 RESPONSIVE COMPANIES
    • 14.7.3 DYNAMIC COMPANIES
    • 14.7.4 STARTING BLOCKS
    • 14.7.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
      • 14.7.5.1 Competitive benchmarking of key startups/SMEs
  • 14.8 COMPANY VALUATION & FINANCIAL METRICS
    • 14.8.1 FINANCIAL METRICS
    • 14.8.2 COMPANY VALUATION
  • 14.9 BRAND/PRODUCT COMPARISON
  • 14.10 COMPETITIVE SCENARIO
    • 14.10.1 PRODUCT APPROVALS
    • 14.10.2 DEALS
    • 14.10.3 EXPANSIONS
    • 14.10.4 OTHER DEVELOPMENTS

15 COMPANY PROFILES

  • 15.1 INTRODUCTION
  • 15.2 KEY PLAYERS
    • 15.2.1 NOVO NORDISK A/S
      • 15.2.1.1 Business overview
      • 15.2.1.2 Products offered
      • 15.2.1.3 Recent developments
        • 15.2.1.3.1 Product approvals
        • 15.2.1.3.2 Deals
        • 15.2.1.3.3 Expansions
        • 15.2.1.3.4 Other developments
      • 15.2.1.4 MnM view
        • 15.2.1.4.1 Right to win
        • 15.2.1.4.2 Strategic choices
        • 15.2.1.4.3 Weaknesses & competitive threats
    • 15.2.2 ELI LILLY AND COMPANY
      • 15.2.2.1 Business overview
      • 15.2.2.2 Products offered
      • 15.2.2.3 Recent developments
        • 15.2.2.3.1 Product approvals
        • 15.2.2.3.2 Deals
        • 15.2.2.3.3 Expansions
      • 15.2.2.4 MnM view
        • 15.2.2.4.1 Right to win
        • 15.2.2.4.2 Strategic choices
        • 15.2.2.4.3 Weaknesses & competitive threats
    • 15.2.3 SANOFI
      • 15.2.3.1 Business overview
      • 15.2.3.2 Products offered
      • 15.2.3.3 MnM view
        • 15.2.3.3.1 Key strengths
        • 15.2.3.3.2 Strategic choices
        • 15.2.3.3.3 Weaknesses & competitive threats
    • 15.2.4 HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED
      • 15.2.4.1 Business overview
      • 15.2.4.2 Products offered
    • 15.2.5 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
      • 15.2.5.1 Business overview
      • 15.2.5.2 Products offered (in pipeline)
      • 15.2.5.3 Recent developments
        • 15.2.5.3.1 Other developments
    • 15.2.6 INNOVENT
      • 15.2.6.1 Business overview
      • 15.2.6.2 Products offered (in pipeline)
      • 15.2.6.3 Recent developments
        • 15.2.6.3.1 Product approvals
        • 15.2.6.3.2 Other developments
    • 15.2.7 PEGBIO CO., LTD.
      • 15.2.7.1 Business overview
      • 15.2.7.2 Products offered (in pipeline)
    • 15.2.8 SCIWIND BIOSCIENCES CO., LTD.
      • 15.2.8.1 Business overview
      • 15.2.8.2 Products offered (in pipeline)
      • 15.2.8.3 Recent developments
        • 15.2.8.3.1 Deals
        • 15.2.8.3.2 Other developments
    • 15.2.9 ZEALAND PHARMA
      • 15.2.9.1 Business overview
      • 15.2.9.2 Products offered (in pipeline)
      • 15.2.9.3 Recent developments
        • 15.2.9.3.1 Deals
        • 15.2.9.3.2 Other developments
    • 15.2.10 STRUCTURE THERAPEUTICS, INC.
      • 15.2.10.1 Business overview
      • 15.2.10.2 Products offered (in pipeline)
      • 15.2.10.3 Recent developments
        • 15.2.10.3.1 Other developments
    • 15.2.11 VIKING THERAPEUTICS
      • 15.2.11.1 Business overview
      • 15.2.11.2 Products offered (in pipeline)
      • 15.2.11.3 Recent developments
        • 15.2.11.3.1 Deals
    • 15.2.12 SUN PHARMACEUTICAL INDUSTRIES LTD.
      • 15.2.12.1 Business overview
      • 15.2.12.2 Products offered (in pipeline)
    • 15.2.13 VTV THERAPEUTICS
      • 15.2.13.1 Business overview
      • 15.2.13.2 Products offered (in pipeline)
    • 15.2.14 ALTIMMUNE
      • 15.2.14.1 Business overview
      • 15.2.14.2 Products offered (in pipeline)
      • 15.2.14.3 Recent developments
        • 15.2.14.3.1 Other developments
    • 15.2.15 AMGEN INC.
      • 15.2.15.1 Business overview
      • 15.2.15.2 Products offered (in pipeline)
    • 15.2.16 GLENMARK PHARMACEUTICALS LTD.
      • 15.2.16.1 Business overview
      • 15.2.16.2 Products offered (in pipeline)
      • 15.2.16.3 Recent developments
        • 15.2.16.3.1 Product launches
    • 15.2.17 BIOCON
      • 15.2.17.1 Business overview
      • 15.2.17.2 Products offered (in pipeline)
      • 15.2.17.3 Recent developments
        • 15.2.17.3.1 Product launches and approvals
        • 15.2.17.3.2 Deals
    • 15.2.18 TEVA PHARMACEUTICAL INDUSTRIES LTD.
      • 15.2.18.1 Business overview
      • 15.2.18.2 Products offered (in pipeline)
      • 15.2.18.3 Recent developments
        • 15.2.18.3.1 Product launches
    • 15.2.19 F. HOFFMANN-LA ROCHE LTD.
      • 15.2.19.1 Business overview
      • 15.2.19.2 Products offered (in pipeline)
      • 15.2.19.3 Recent developments
        • 15.2.19.3.1 Deals
  • 15.3 OTHER PLAYERS
    • 15.3.1 TERNS PHARMACEUTICALS, INC.
    • 15.3.2 METAVIA
    • 15.3.3 SCOHIA PHARMA, INC.
    • 15.3.4 REGOR THERAPEUTICS GROUP
    • 15.3.5 NEURALY INC.
    • 15.3.6 I2O THERAPEUTICS, INC.
    • 15.3.7 PFIZER INC.
    • 15.3.8 HANMI PHARM CO.,LTD.
    • 15.3.9 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.
    • 15.3.10 BIOMED INDUSTRIES, INC.

16 APPENDIX

  • 16.1 DISCUSSION GUIDE
  • 16.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 16.3 CUSTOMIZATION OPTIONS
  • 16.4 RELATED REPORTS
  • 16.5 AUTHOR DETAILS

List of Tables

  • TABLE 1 GLP-1 AGONISTS MARKET: INCLUSIONS & EXCLUSIONS
  • TABLE 2 GLP-1 AGONISTS MARKET: RISK ANALYSIS
  • TABLE 3 GLP-1 AGONISTS MARKET: STRATEGIC ANALYSIS OF GROWTH OPPORTUNITIES
  • TABLE 4 GLP-1 AGONISTS MARKET: EMERGING BUSINESS MODELS & TARGET SEGMENTS
  • TABLE 5 EXPECTED KEY LAUNCHES IN GLP-1 AGONISTS MARKET, 2025-2033
  • TABLE 6 GLP-1 AGONISTS MARKET: IMPACT ANALYSIS
  • TABLE 7 KEY GLP-1 AGONISTS PIPELINE & EXPECTED LAUNCHES
  • TABLE 8 AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY KEY PLAYER, 2022-2024 (USD)
  • TABLE 9 AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY REGION, 2022-2024 (USD)
  • TABLE 10 GLP-1 AGONISTS IN CLINICAL PIPELINE (AS OF SEPTEMBER 2025)
  • TABLE 11 GLP-1 AGONISTS MARKET: ROLE IN ECOSYSTEM
  • TABLE 12 GLP-1 AGONISTS MARKET: PORTER'S FIVE FORCES
  • TABLE 13 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 14 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 15 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 16 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 17 LIST OF KEY CONFERENCES & EVENTS IN GLP-1 AGONISTS MARKET, JANUARY 2025-DECEMBER 2026
  • TABLE 18 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY TYPE
  • TABLE 19 BUYING CRITERIA FOR GLP-1 AGONIST PRODUCTS, BY END USER
  • TABLE 20 GLP-1 AGONISTS: ADOPTION BARRIER & INTERNAL FRICTION
  • TABLE 21 KEY COMPANIES IMPLEMENTING AI IN GLP-1 AGONISTS MARKET
  • TABLE 22 GLP-1 AGONISTS MARKET, BY PRODUCT, 2024-2033 (USD BILLION)
  • TABLE 23 GLP-1 AGONISTS MARKET, BY PRODUCT, 2024-2033 (MILLION UNITS)
  • TABLE 24 GLP-1 AGONISTS MARKET FOR OZEMPIC, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 25 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR OZEMPIC, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 26 EUROPE: GLP-1 AGONISTS MARKET FOR OZEMPIC, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 27 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR OZEMPIC, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 28 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR OZEMPIC, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 29 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR OZEMPIC, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 30 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR OZEMPIC, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 31 GLP-1 AGONISTS MARKET FOR TRULICITY, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 32 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR TRULICITY, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 33 EUROPE: GLP-1 AGONISTS MARKET FOR TRULICITY, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 34 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR TRULICITY, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 35 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR TRULICITY, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 36 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR TRULICITY, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 37 GLP-1 AGONISTS MARKET FOR MOUNJARO, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 38 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR MOUNJARO, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 39 EUROPE: GLP-1 AGONISTS MARKET FOR MOUNJARO, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 40 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR MOUNJARO, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 41 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR MOUNJARO, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 42 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR MOUNJARO, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 43 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR MOUNJARO, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 44 GLP-1 AGONISTS MARKET FOR WEGOVY, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 45 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR WEGOVY, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 46 EUROPE: GLP-1 AGONISTS MARKET FOR WEGOVY, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 47 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR WEGOVY, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 48 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR WEGOVY, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 49 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR WEGOVY, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 50 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR WEGOVY, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 51 GLP-1 AGONISTS MARKET FOR RYBELSUS, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 52 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR RYBELSUS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 53 EUROPE: GLP-1 AGONISTS MARKET FOR RYBELSUS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 54 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR RYBELSUS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 55 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR RYBELSUS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 56 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR RYBELSUS, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 57 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR RYBELSUS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 58 GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 59 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY COUNTRY, S2024-2033 (USD BILLION)
  • TABLE 60 EUROPE: GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 61 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 62 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 63 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 64 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR ZEPBOUND, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 65 GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 66 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 67 EUROPE: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 68 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 69 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 70 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 71 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 72 GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 73 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 74 EUROPE: GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 75 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 76 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 77 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 78 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR CAGRISEMA, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 79 GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 80 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 81 EUROPE: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 82 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 83 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 84 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 85 GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 86 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 87 EUROPE: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 88 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 89 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 90 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 91 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 92 GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 93 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 94 EUROPE: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 95 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 96 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 97 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 98 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE BIOSIMILARS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 99 GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 100 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 101 EUROPE: GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 102 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 103 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 104 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 105 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR OTHER GLP-1 BIOSIMILARS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 106 GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 107 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 108 EUROPE: GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 109 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 110 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 111 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 112 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR OTHER PRODUCTS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 113 GLP-1 AGONISTS MARKET, BY MOLECULE, 2024-2033 (USD BILLION)
  • TABLE 114 GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 115 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 116 EUROPE: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 117 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 118 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 119 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 120 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SEMAGLUTIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 121 GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 122 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 123 EUROPE: GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 124 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 125 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 126 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 127 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR TIRZEPATIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 128 GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 129 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 130 EUROPE: GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 131 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 132 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 133 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 134 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR DULAGLUTIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 135 GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 136 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 137 EUROPE: GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 138 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 139 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 140 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 141 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR CAGRILINTIDE SEMAGLUTIDE COMBINATION, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 142 GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 143 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 144 EUROPE: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 145 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 146 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 147 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 148 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR ORFORGLIPRON, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 149 GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 150 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 151 EUROPE: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 152 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 153 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 154 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 155 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SURVODUTIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 156 GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 157 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 158 EUROPE: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 159 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 160 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 161 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 162 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR RETATRUTIDE, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 163 GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 164 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 165 EUROPE: GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 166 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 167 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 168 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 169 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR OTHER MOLECULES, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 170 GLP-1 AGONISTS MARKET, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 171 GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 172 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 173 EUROPE: GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 174 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 175 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 176 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 177 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR PATENTED PRODUCTS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 178 GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 179 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 180 EUROPE: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 181 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 182 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 183 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 184 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 185 GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 186 SEMAGLUTIDE BIOSIMILARS MARKET, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 187 NORTH AMERICA: SEMAGLUTIDE BIOSIMILARS MARKET, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 188 EUROPE: SEMAGLUTIDE BIOSIMILARS MARKET, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 189 ASIA PACIFIC: SEMAGLUTIDE BIOSIMILARS MARKET, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 190 LATIN AMERICA: SEMAGLUTIDE BIOSIMILARS MARKET, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 191 MIDDLE EAST: SEMAGLUTIDE BIOSIMILARS MARKET, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 192 GCC COUNTRIES: SEMAGLUTIDE BIOSIMILARS MARKET, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 193 OTHER BIOSIMILARS MARKET, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 194 NORTH AMERICA: OTHER BIOSIMILARS MARKET, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 195 EUROPE: OTHER BIOSIMILARS MARKET, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 196 ASIA PACIFIC: OTHER BIOSIMILARS MARKET, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 197 LATIN AMERICA: OTHER BIOSIMILARS MARKET, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 198 MIDDLE EAST: OTHER BIOSIMILARS MARKET, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 199 GCC COUNTRIES: OTHER BIOSIMILARS MARKET, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 200 GLP-1 AGONISTS MARKET, BY INDICATION, 2024-2033 (USD BILLION)
  • TABLE 201 GLP-1 AGONISTS MARKET FOR DIABETES, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 202 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR DIABETES, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 203 EUROPE: GLP-1 AGONISTS MARKET FOR DIABETES, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 204 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR DIABETES, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 205 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR DIABETES, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 206 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR DIABETES, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 207 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR DIABETES, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 208 GLP-1 AGONISTS MARKET FOR OBESITY, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 209 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR OBESITY, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 210 EUROPE: GLP-1 AGONISTS MARKET FOR OBESITY, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 211 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR OBESITY, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 212 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR OBESITY, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 213 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR OBESITY, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 214 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR OBESITY, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 215 GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 216 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 217 EUROPE: GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 218 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 219 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 220 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 221 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR OTHER INDICATIONS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 222 GLP-1 AGONISTS MARKET, BY FORMAT, 2024-2033 (USD BILLION)
  • TABLE 223 GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 224 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 225 EUROPE: GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 226 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 227 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 228 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 229 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SINGLE-DOSE FORMATS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 230 GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 231 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 232 EUROPE: GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 233 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 234 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 235 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 236 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR MULTI-DOSE FORMATS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 237 GLP-1 AGONISTS MARKET FOR TABLETS, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 238 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR TABLETS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 239 EUROPE: GLP-1 AGONISTS MARKET FOR TABLETS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 240 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR TABLETS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 241 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR TABLETS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 242 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR TABLETS, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 243 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR TABLETS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 244 GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2033 (USD BILLION)
  • TABLE 245 GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 246 GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 247 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 248 EUROPE: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 249 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 250 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 251 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 252 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 253 PEN INJECTORS MARKET, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 254 NORTH AMERICA: PEN INJECTORS MARKET, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 255 EUROPE: PEN INJECTORS MARKET, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 256 ASIA PACIFIC: PEN INJECTORS MARKET, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 257 LATIN AMERICA: PEN INJECTORS MARKET, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 258 MIDDLE EAST: PEN INJECTORS MARKET, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 259 GCC COUNTRIES: PEN INJECTORS MARKET, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 260 AUTOINJECTORS MARKET, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 261 NORTH AMERICA: AUTOINJECTORS MARKET, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 262 EUROPE: AUTOINJECTORS MARKET, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 263 ASIA PACIFIC: AUTOINJECTORS MARKET, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 264 LATIN AMERICA: AUTOINJECTORS MARKET, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 265 MIDDLE EAST: AUTOINJECTORS MARKET, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 266 GCC COUNTRIES: AUTOINJECTORS MARKET, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 267 GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 268 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 269 EUROPE: GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 270 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 271 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 272 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 273 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR ORAL ADMINISTRATION, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 274 GLP-1 AGONISTS MARKET, BY END USER, 2024-2033 (USD BILLION)
  • TABLE 275 GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 276 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 277 EUROPE: GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 278 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 279 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 280 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 281 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 282 GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 283 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 284 EUROPE: GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 285 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 286 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 287 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 288 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 289 GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 290 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 291 EUROPE: GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 292 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 293 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 294 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 295 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR HOSPITALS & SPECIALTY CLINICS, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 296 GLP-1 AGONISTS MARKET, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 297 NORTH AMERICA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024-2033 (USD BILLION)
  • TABLE 298 NORTH AMERICA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024-2033 (USD BILLION)
  • TABLE 299 NORTH AMERICA: GLP-1 AGONISTS MARKET, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 300 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 301 NORTH AMERICA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024-2033 (USD BILLION)
  • TABLE 302 NORTH AMERICA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024-2033 (USD BILLION)
  • TABLE 303 NORTH AMERICA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2033 (USD BILLION)
  • TABLE 304 NORTH AMERICA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 305 NORTH AMERICA: GLP-1 AGONISTS MARKET, BY END USER, 2024-2033 (USD BILLION)
  • TABLE 306 NORTH AMERICA: GLP-1 AGONISTS MARKET, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 307 NORTH AMERICA: KEY MACROINDICATORS
  • TABLE 308 US: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024-2033 (USD BILLION)
  • TABLE 309 US: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024-2033 (USD BILLION)
  • TABLE 310 US: GLP-1 AGONISTS MARKET, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 311 US: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 312 US: GLP-1 AGONISTS MARKET, BY INDICATION, 2024-2033 (USD BILLION)
  • TABLE 313 US: GLP-1 AGONISTS MARKET, BY FORMAT, 2024-2033 (USD BILLION)
  • TABLE 314 US: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2033 (USD BILLION)
  • TABLE 315 US: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 316 US: GLP-1 AGONISTS MARKET, BY END USER, 2024-2033 (USD BILLION)
  • TABLE 317 CANADA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024-2033 (USD BILLION)
  • TABLE 318 CANADA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024-2033 (USD BILLION)
  • TABLE 319 CANADA: GLP-1 AGONISTS MARKET, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 320 CANADA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 321 CANADA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024-2033 (USD BILLION)
  • TABLE 322 CANADA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024-2033 (USD BILLION)
  • TABLE 323 CANADA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2033 (USD BILLION)
  • TABLE 324 CANADA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 325 CANADA: GLP-1 AGONISTS MARKET, BY END USER, 2024-2033 (USD BILLION)
  • TABLE 326 EUROPE: GLP-1 AGONISTS MARKET, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 327 EUROPE: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024-2033 (USD BILLION)
  • TABLE 328 EUROPE: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024-2033 (USD BILLION)
  • TABLE 329 EUROPE: GLP-1 AGONISTS MARKET, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 330 EUROPE: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 331 EUROPE: GLP-1 AGONISTS MARKET, BY INDICATION, 2024-2033 (USD BILLION)
  • TABLE 332 EUROPE: GLP-1 AGONISTS MARKET, BY FORMAT, 2024-2033 (USD BILLION)
  • TABLE 333 EUROPE: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2033 (USD BILLION)
  • TABLE 334 EUROPE: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 335 EUROPE: GLP-1 AGONISTS MARKET, BY END USER, 2024-2033 (USD BILLION)
  • TABLE 336 EUROPE: KEY MACROINDICATORS
  • TABLE 337 GERMANY: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024-2033 (USD BILLION)
  • TABLE 338 GERMANY: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024-2033 (USD BILLION)
  • TABLE 339 GERMANY: GLP-1 AGONISTS MARKET, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 340 GERMANY: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 341 GERMANY: GLP-1 AGONISTS MARKET, BY INDICATION, 2024-2033 (USD BILLION)
  • TABLE 342 GERMANY: GLP-1 AGONISTS MARKET, BY FORMAT, 2024-2033 (USD BILLION)
  • TABLE 343 GERMANY: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2033 (USD BILLION)
  • TABLE 344 GERMANY: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 345 GERMANY: GLP-1 AGONISTS MARKET, BY END USER, 2024-2033 (USD BILLION)
  • TABLE 346 UK: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024-2033 (USD BILLION)
  • TABLE 347 UK: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024-2033 (USD BILLION)
  • TABLE 348 UK: GLP-1 AGONISTS MARKET, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 349 UK: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 350 UK: GLP-1 AGONISTS MARKET, BY INDICATION, 2024-2033 (USD BILLION)
  • TABLE 351 UK: GLP-1 AGONISTS MARKET, BY FORMAT, 2024-2033 (USD BILLION)
  • TABLE 352 UK: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2033 (USD BILLION)
  • TABLE 353 UK: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 354 UK: GLP-1 AGONISTS MARKET, BY END USER, 2024-2033 (USD BILLION)
  • TABLE 355 FRANCE: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024-2033 (USD BILLION)
  • TABLE 356 FRANCE: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024-2033 (USD BILLION)
  • TABLE 357 FRANCE: GLP-1 AGONISTS MARKET, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 358 FRANCE: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 359 FRANCE: GLP-1 AGONISTS MARKET, BY INDICATION, 2024-2033 (USD BILLION)
  • TABLE 360 FRANCE: GLP-1 AGONISTS MARKET, BY FORMAT, 2024-2033 (USD BILLION)
  • TABLE 361 FRANCE: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2033 (USD BILLION)
  • TABLE 362 FRANCE: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 363 FRANCE: GLP-1 AGONISTS MARKET, BY END USER, 2024-2033 (USD BILLION)
  • TABLE 364 ITALY: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024-2033 (USD BILLION)
  • TABLE 365 ITALY: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024-2033 (USD BILLION)
  • TABLE 366 ITALY: GLP-1 AGONISTS MARKET, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 367 ITALY: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 368 ITALY: GLP-1 AGONISTS MARKET, BY INDICATION, 2024-2033 (USD BILLION)
  • TABLE 369 ITALY: GLP-1 AGONISTS MARKET, BY FORMAT, 2024-2033 (USD BILLION)
  • TABLE 370 ITALY: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2033 (USD BILLION)
  • TABLE 371 ITALY: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 372 ITALY: GLP-1 AGONISTS MARKET, BY END USER, 2024-2033 (USD BILLION)
  • TABLE 373 SPAIN: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024-2033 (USD BILLION)
  • TABLE 374 SPAIN: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024-2033 (USD BILLION)
  • TABLE 375 SPAIN: GLP-1 AGONISTS MARKET, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 376 SPAIN: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 377 SPAIN: GLP-1 AGONISTS MARKET, BY INDICATION, 2024-2033 (USD BILLION)
  • TABLE 378 SPAIN: GLP-1 AGONISTS MARKET, BY FORMAT, 2024-2033 (USD BILLION)
  • TABLE 379 SPAIN: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2033 (USD BILLION)
  • TABLE 380 SPAIN: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 381 SPAIN: GLP-1 AGONISTS MARKET, BY END USER, 2024-2033 (USD BILLION)
  • TABLE 382 NETHERLANDS: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024-2033 (USD BILLION)
  • TABLE 383 NETHERLANDS: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024-2033 (USD BILLION)
  • TABLE 384 NETHERLANDS: GLP-1 AGONISTS MARKET, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 385 NETHERLANDS: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 386 NETHERLANDS: GLP-1 AGONISTS MARKET, BY INDICATION, 2024-2033 (USD BILLION)
  • TABLE 387 NETHERLANDS: GLP-1 AGONISTS MARKET, BY FORMAT, 2024-2033 (USD BILLION)
  • TABLE 388 NETHERLANDS: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2033 (USD BILLION)
  • TABLE 389 NETHERLANDS: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 390 NETHERLANDS: GLP-1 AGONISTS MARKET, BY END USER, 2024-2033 (USD BILLION)
  • TABLE 391 REST OF EUROPE: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024-2033 (USD BILLION)
  • TABLE 392 REST OF EUROPE: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024-2033 (USD BILLION)
  • TABLE 393 REST OF EUROPE: GLP-1 AGONISTS MARKET, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 394 REST OF EUROPE: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 395 REST OF EUROPE: GLP-1 AGONISTS MARKET, BY INDICATION, 2024-2033 (USD BILLION)
  • TABLE 396 REST OF EUROPE: GLP-1 AGONISTS MARKET, BY FORMAT, 2024-2033 (USD BILLION)
  • TABLE 397 REST OF EUROPE: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2033 (USD BILLION)
  • TABLE 398 REST OF EUROPE: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 399 REST OF EUROPE: GLP-1 AGONISTS MARKET, BY END USER, 2024-2033 (USD BILLION)
  • TABLE 400 ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 401 ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024-2033 (USD BILLION)
  • TABLE 402 ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024-2033 (USD BILLION)
  • TABLE 403 ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 404 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 405 ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY INDICATION, 2024-2033 (USD BILLION)
  • TABLE 406 ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY FORMAT, 2024-2033 (USD BILLION)
  • TABLE 407 ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2033 (USD BILLION)
  • TABLE 408 ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 409 ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY END USER, 2024-2033 (USD BILLION)
  • TABLE 410 ASIA PACIFIC: KEY MACROINDICATORS
  • TABLE 411 CHINA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024-2033 (USD BILLION)
  • TABLE 412 CHINA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024-2033 (USD BILLION)
  • TABLE 413 CHINA: GLP-1 AGONISTS MARKET, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 414 CHINA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 415 CHINA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024-2033 (USD BILLION)
  • TABLE 416 CHINA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024-2033 (USD BILLION)
  • TABLE 417 CHINA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2033 (USD BILLION)
  • TABLE 418 CHINA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 419 CHINA: GLP-1 AGONISTS MARKET, BY END USER, 2024-2033 (USD BILLION)
  • TABLE 420 JAPAN: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024-2033 (USD BILLION)
  • TABLE 421 JAPAN: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024-2033 (USD BILLION)
  • TABLE 422 JAPAN: GLP-1 AGONISTS MARKET, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 423 JAPAN: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 424 JAPAN: GLP-1 AGONISTS MARKET, BY INDICATION, 2024-2033 (USD BILLION)
  • TABLE 425 JAPAN: GLP-1 AGONISTS MARKET, BY FORMAT, 2024-2033 (USD BILLION)
  • TABLE 426 JAPAN: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2033 (USD BILLION)
  • TABLE 427 JAPAN: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 428 JAPAN: GLP-1 AGONISTS MARKET, BY END USER, 2024-2033 (USD BILLION)
  • TABLE 429 INDIA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024-2033 (USD BILLION)
  • TABLE 430 INDIA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024-2033 (USD BILLION)
  • TABLE 431 INDIA: GLP-1 AGONISTS MARKET, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 432 INDIA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 433 INDIA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024-2033 (USD BILLION)
  • TABLE 434 INDIA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024-2033 (USD BILLION)
  • TABLE 435 INDIA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2033 (USD BILLION)
  • TABLE 436 INDIA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 437 INDIA: GLP-1 AGONISTS MARKET, BY END USER, 2024-2033 (USD BILLION)
  • TABLE 438 AUSTRALIA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024-2033 (USD BILLION)
  • TABLE 439 AUSTRALIA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024-2033 (USD BILLION)
  • TABLE 440 AUSTRALIA: GLP-1 AGONISTS MARKET, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 441 AUSTRALIA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 442 AUSTRALIA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024-2033 (USD BILLION)
  • TABLE 443 AUSTRALIA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024-2033 (USD BILLION)
  • TABLE 444 AUSTRALIA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2033 (USD BILLION)
  • TABLE 445 AUSTRALIA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 446 AUSTRALIA: GLP-1 AGONISTS MARKET, BY END USER, 2024-2033 (USD BILLION)
  • TABLE 447 SOUTH KOREA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024-2033 (USD BILLION)
  • TABLE 448 SOUTH KOREA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024-2033 (USD BILLION)
  • TABLE 449 SOUTH KOREA: GLP-1 AGONISTS MARKET, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 450 SOUTH KOREA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 451 SOUTH KOREA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024-2033 (USD BILLION)
  • TABLE 452 SOUTH KOREA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024-2033 (USD BILLION)
  • TABLE 453 SOUTH KOREA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2033 (USD BILLION)
  • TABLE 454 SOUTH KOREA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 455 SOUTH KOREA: GLP-1 AGONISTS MARKET, BY END USER, 2024-2033 (USD BILLION)
  • TABLE 456 REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024-2033 (USD BILLION)
  • TABLE 457 REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024-2033 (USD BILLION)
  • TABLE 458 REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 459 REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 460 REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY INDICATION, 2024-2033 (USD BILLION)
  • TABLE 461 REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY FORMAT, 2024-2033 (USD BILLION)
  • TABLE 462 REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2033 (USD BILLION)
  • TABLE 463 REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 464 REST OF ASIA PACIFIC: GLP-1 AGONISTS MARKET, BY END USER, 2024-2033 (USD BILLION)
  • TABLE 465 LATIN AMERICA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024-2033 (USD BILLION)
  • TABLE 466 LATIN AMERICA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024-2033 (USD BILLION)
  • TABLE 467 LATIN AMERICA: GLP-1 AGONISTS MARKET, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 468 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 469 LATIN AMERICA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024-2033 (USD BILLION)
  • TABLE 470 LATIN AMERICA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024-2033 (USD BILLION)
  • TABLE 471 LATIN AMERICA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2033 (USD BILLION)
  • TABLE 472 LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 473 LATIN AMERICA: GLP-1 AGONISTS MARKET, BY END USER, 2024-2033 (USD BILLION)
  • TABLE 474 LATIN AMERICA: GLP-1 AGONISTS MARKET, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 475 LATIN AMERICA: KEY MACROINDICATORS
  • TABLE 476 BRAZIL: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024-2033 (USD BILLION)
  • TABLE 477 BRAZIL: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024-2033 (USD BILLION)
  • TABLE 478 BRAZIL: GLP-1 AGONISTS MARKET, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 479 BRAZIL: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 480 BRAZIL: GLP-1 AGONISTS MARKET, BY INDICATION, 2024-2033 (USD BILLION)
  • TABLE 481 BRAZIL: GLP-1 AGONISTS MARKET, BY FORMAT, 2024-2033 (USD BILLION)
  • TABLE 482 BRAZIL: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2033 (USD BILLION)
  • TABLE 483 BRAZIL: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 484 BRAZIL: GLP-1 AGONISTS MARKET, BY END USER, 2024-2033 (USD BILLION)
  • TABLE 485 MEXICO: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024-2033 (USD BILLION)
  • TABLE 486 MEXICO: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024-2033 (USD BILLION)
  • TABLE 487 MEXICO: GLP-1 AGONISTS MARKET, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 488 MEXICO: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 489 MEXICO: GLP-1 AGONISTS MARKET, BY INDICATION, 2024-2033 (USD BILLION)
  • TABLE 490 MEXICO: GLP-1 AGONISTS MARKET, BY FORMAT, 2024-2033 (USD BILLION)
  • TABLE 491 MEXICO: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2033 (USD BILLION)
  • TABLE 492 MEXICO: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 493 MEXICO: GLP-1 AGONISTS MARKET, BY END USER, 2024-2033 (USD BILLION)
  • TABLE 494 REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024-2033 (USD BILLION)
  • TABLE 495 REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024-2033 (USD BILLION)
  • TABLE 496 REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 497 REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 498 REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024-2033 (USD BILLION)
  • TABLE 499 REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024-2033 (USD BILLION)
  • TABLE 500 REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2033 (USD BILLION)
  • TABLE 501 REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 502 REST OF LATIN AMERICA: GLP-1 AGONISTS MARKET, BY END USER, 2024-2033 (USD BILLION)
  • TABLE 503 MIDDLE EAST: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024-2033 (USD BILLION)
  • TABLE 504 MIDDLE EAST: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024-2033 (USD BILLION)
  • TABLE 505 MIDDLE EAST: GLP-1 AGONISTS MARKET, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 506 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 507 MIDDLE EAST: GLP-1 AGONISTS MARKET, BY INDICATION, 2024-2033 (USD BILLION)
  • TABLE 508 MIDDLE EAST: GLP-1 AGONISTS MARKET, BY FORMAT, 2024-2033 (USD BILLION)
  • TABLE 509 MIDDLE EAST: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2033 (USD BILLION)
  • TABLE 510 MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 511 MIDDLE EAST: GLP-1 AGONISTS MARKET, BY END USER, 2024-2033 (USD BILLION)
  • TABLE 512 MIDDLE EAST: GLP-1 AGONISTS MARKET, BY REGION, 2024-2033 (USD BILLION)
  • TABLE 513 MIDDLE EAST: KEY MACROINDICATORS
  • TABLE 514 GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024-2033 (USD BILLION)
  • TABLE 515 GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024-2033 (USD BILLION)
  • TABLE 516 GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 517 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 518 GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY INDICATION, 2024-2033 (USD BILLION)
  • TABLE 519 GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY FORMAT, 2024-2033 (USD BILLION)
  • TABLE 520 GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2033 (USD BILLION)
  • TABLE 521 GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 522 GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY END USER, 2024-2033 (USD BILLION)
  • TABLE 523 GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY COUNTRY, 2024-2033 (USD BILLION)
  • TABLE 524 KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024-2033 (USD BILLION)
  • TABLE 525 KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024-2033 (USD BILLION)
  • TABLE 526 KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 527 KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 528 KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024-2033 (USD BILLION)
  • TABLE 529 KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024-2033 (USD BILLION)
  • TABLE 530 KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2033 (USD BILLION)
  • TABLE 531 KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 532 KINGDOM OF SAUDI ARABIA: GLP-1 AGONISTS MARKET, BY END USER, 2024-2033 (USD BILLION)
  • TABLE 533 UAE: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024-2033 (USD BILLION)
  • TABLE 534 UAE: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024-2033 (USD BILLION)
  • TABLE 535 UAE: GLP-1 AGONISTS MARKET, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 536 UAE: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 537 UAE: GLP-1 AGONISTS MARKET, BY INDICATION, 2024-2033 (USD BILLION)
  • TABLE 538 UAE: GLP-1 AGONISTS MARKET, BY FORMAT, 2024-2033 (USD BILLION)
  • TABLE 539 UAE: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2033 (USD BILLION)
  • TABLE 540 UAE: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 541 UAE: GLP-1 AGONISTS MARKET, BY END USER, 2024-2033 (USD BILLION)
  • TABLE 542 REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024-2033 (USD BILLION)
  • TABLE 543 REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024-2033 (USD BILLION)
  • TABLE 544 REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 545 REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 546 REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY INDICATION, 2024-2033 (USD BILLION)
  • TABLE 547 REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY FORMAT, 2024-2033 (USD BILLION)
  • TABLE 548 REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2033 (USD BILLION)
  • TABLE 549 REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 550 REST OF GCC COUNTRIES: GLP-1 AGONISTS MARKET, BY END USER, 2024-2033 (USD BILLION)
  • TABLE 551 REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024-2033 (USD BILLION)
  • TABLE 552 REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024-2033 (USD BILLION)
  • TABLE 553 REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 554 REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 555 REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET, BY INDICATION, 2024-2033 (USD BILLION)
  • TABLE 556 REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET, BY FORMAT, 2024-2033 (USD BILLION)
  • TABLE 557 REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2033 (USD BILLION)
  • TABLE 558 REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 559 REST OF MIDDLE EAST: GLP-1 AGONISTS MARKET, BY END USER, 2024-2033 (USD BILLION)
  • TABLE 560 AFRICA: GLP-1 AGONISTS MARKET, BY PRODUCT, 2024-2033 (USD BILLION)
  • TABLE 561 AFRICA: GLP-1 AGONISTS MARKET, BY MOLECULE, 2024-2033 (USD BILLION)
  • TABLE 562 AFRICA: GLP-1 AGONISTS MARKET, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 563 AFRICA: GLP-1 AGONISTS MARKET FOR BIOSIMILARS, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 564 AFRICA: GLP-1 AGONISTS MARKET, BY INDICATION, 2024-2033 (USD BILLION)
  • TABLE 565 AFRICA: GLP-1 AGONISTS MARKET, BY FORMAT, 2024-2033 (USD BILLION)
  • TABLE 566 AFRICA: GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2024-2033 (USD BILLION)
  • TABLE 567 AFRICA: GLP-1 AGONISTS MARKET FOR SUBCUTANEOUS ADMINISTRATION, BY TYPE, 2024-2033 (USD BILLION)
  • TABLE 568 AFRICA: GLP-1 AGONISTS MARKET, BY END USER, 2024-2033 (USD BILLION)
  • TABLE 569 AFRICA: KEY MACROINDICATORS
  • TABLE 570 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN GLP-1 AGONISTS MARKET
  • TABLE 571 GLP-1 AGONISTS MARKET: DEGREE OF COMPETITION
  • TABLE 572 GLP-1 AGONISTS MARKET: REGION FOOTPRINT (KEY PLAYERS)
  • TABLE 573 GLP-1 AGONISTS MARKET: REGION FOOTPRINT (PRODUCTS IN PIPELINE)
  • TABLE 574 GLP-1 AGONISTS MARKET: FORMAT FOOTPRINT
  • TABLE 575 GLP-1 AGONISTS MARKET: ROUTE OF ADMINISTRATION FOOTPRINT
  • TABLE 576 GLP-1 AGONISTS MARKET: INDICATION FOOTPRINT (KEY PLAYERS)
  • TABLE 577 GLP-1 AGONISTS MARKET: INDICATION FOOTPRINT (PRODUCTS IN PIPELINE)
  • TABLE 578 GLP-1 AGONISTS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
  • TABLE 579 GLP-1 AGONISTS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY INDICATION AND REGION
  • TABLE 580 GLP-1 AGONISTS MARKET: PRODUCT APPROVALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 581 GLP-1 AGONISTS MARKET: DEALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 582 GLP-1 AGONISTS MARKET: EXPANSIONS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 583 GLP-1 AGONISTS MARKET: OTHER DEVELOPMENTS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 584 NOVO NORDISK A/S: COMPANY OVERVIEW
  • TABLE 585 NOVO NORDISK A/S: PRODUCTS OFFERED
  • TABLE 586 NOVO NORDISK A/S: PRODUCT APPROVALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 587 NOVO NORDISK A/S: DEALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 588 NOVO NORDISK A/S: EXPANSIONS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 589 NOVO NORDISK A/S: OTHER DEVELOPMENTS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 590 ELI LILLY AND COMPANY: COMPANY OVERVIEW
  • TABLE 591 ELI LILLY AND COMPANY: PRODUCTS OFFERED
  • TABLE 592 ELI LILLY AND COMPANY: PRODUCT APPROVALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 593 ELI LILLY AND COMPANY: DEALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 594 ELI LILLY AND COMPANY: EXPANSIONS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 595 SANOFI: COMPANY OVERVIEW
  • TABLE 596 SANOFI: PRODUCTS OFFERED
  • TABLE 597 HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED: COMPANY OVERVIEW
  • TABLE 598 HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED: PRODUCTS OFFERED
  • TABLE 599 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW
  • TABLE 600 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: PRODUCTS OFFERED (IN PIPELINE)
  • TABLE 601 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: OTHER DEVELOPMENTS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 602 INNOVENT: COMPANY OVERVIEW
  • TABLE 603 INNOVENT: PRODUCTS OFFERED (IN PIPELINE)
  • TABLE 604 INNOVENT: PRODUCT APPROVALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 605 INNOVENT: OTHER DEVELOPMENTS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 606 PEGBIO CO., LTD.: COMPANY OVERVIEW
  • TABLE 607 PEGBIO CO., LTD.: PRODUCTS OFFERED (IN PIPELINE)
  • TABLE 608 SCIWIND BIOSCIENCES CO., LTD.: COMPANY OVERVIEW
  • TABLE 609 SCIWIND BIOSCIENCES CO., LTD.: PRODUCTS OFFERED (IN PIPELINE)
  • TABLE 610 SCIWIND BIOSCIENCES CO., LTD.: DEALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 611 SCIWIND BIOSCIENCES CO., LTD.: OTHER DEVELOPMENTS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 612 ZEALAND PHARMA: COMPANY OVERVIEW
  • TABLE 613 ZEALAND PHARMA: PRODUCTS OFFERED (IN PIPELINE)
  • TABLE 614 ZEALAND PHARMA: DEALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 615 ZEALAND PHARMA: OTHER DEVELOPMENTS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 616 STRUCTURE THERAPEUTICS, INC.: COMPANY OVERVIEW
  • TABLE 617 STRUCTURE THERAPEUTICS, INC.: PRODUCTS OFFERED (IN PIPELINE)
  • TABLE 618 STRUCTURE THERAPEUTICS, INC.: OTHER DEVELOPMENTS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 619 VIKING THERAPEUTICS: COMPANY OVERVIEW
  • TABLE 620 VIKING THERAPEUTICS: PRODUCTS OFFERED (IN PIPELINE)
  • TABLE 621 VIKING THERAPEUTICS: DEALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 622 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
  • TABLE 623 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED (IN PIPELINE)
  • TABLE 624 VTV THERAPEUTICS: COMPANY OVERVIEW
  • TABLE 625 VTV THERAPEUTICS: PRODUCTS OFFERED (IN PIPELINE)
  • TABLE 626 ALTIMMUNE: COMPANY OVERVIEW
  • TABLE 627 ALTIMMUNE: PRODUCTS OFFERED (IN PIPELINE)
  • TABLE 628 ALTIMMUNE: OTHER DEVELOPMENTS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 629 AMGEN INC.: COMPANY OVERVIEW
  • TABLE 630 AMGEN INC.: PRODUCTS OFFERED (IN PIPELINE)
  • TABLE 631 GLENMARK PHARMACEUTICALS LTD.: COMPANY OVERVIEW
  • TABLE 632 GLENMARK PHARMACEUTICALS LTD.: PRODUCTS OFFERED (IN PIPELINE)
  • TABLE 633 GLENMARK PHARMACEUTICALS LTD.: PRODUCT LAUNCHES, JANUARY 2022-SEPTEMBER 2025
  • TABLE 634 BIOCON: COMPANY OVERVIEW
  • TABLE 635 BIOCON: PRODUCTS OFFERED (IN PIPELINE)
  • TABLE 636 BIOCON: PRODUCT LAUNCHES AND APPROVALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 637 BIOCON: DEALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 638 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW
  • TABLE 639 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT OFFERED (IN PIPELINE)
  • TABLE 640 TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT LAUNCHES, JANUARY 2022-SEPTEMBER 2025
  • TABLE 641 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 642 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED (IN PIPELINE)
  • TABLE 643 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2022-SEPTEMBER 2025
  • TABLE 644 TERNS PHARMACEUTICALS, INC.: COMPANY OVERVIEW
  • TABLE 645 METAVIA: COMPANY OVERVIEW
  • TABLE 646 SCOHIA PHARMA, INC.: COMPANY OVERVIEW
  • TABLE 647 REGOR THERAPEUTICS GROUP: COMPANY OVERVIEW
  • TABLE 648 NEURALY INC.: COMPANY OVERVIEW
  • TABLE 649 I2O THERAPEUTICS, INC.: COMPANY OVERVIEW
  • TABLE 650 PFIZER INC.: COMPANY OVERVIEW
  • TABLE 651 HANMI PHARM CO., LTD.: COMPANY OVERVIEW
  • TABLE 652 JIANGSU HENGRUI PHARMACEUTICALS CO., LTD.: COMPANY OVERVIEW
  • TABLE 653 BIOMED INDUSTRIES, INC.: COMPANY OVERVIEW

List of Figures

  • FIGURE 1 GLP-1 AGONISTS MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 GLP-1 AGONISTS MARKET: YEARS CONSIDERED
  • FIGURE 3 GLP-1 AGONISTS MARKET: RESEARCH DESIGN
  • FIGURE 4 BREAKDOWN OF PRIMARIES: SUPPLY- AND DEMAND-SIDE PARTICIPANTS
  • FIGURE 5 GLP-1 AGONISTS MARKET SIZE ESTIMATION (SUPPLY-SIDE ANALYSIS), 2024
  • FIGURE 6 GLP-1 AGONISTS MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS, 2024
  • FIGURE 7 MARKET VALIDATION FROM PRIMARY EXPERTS
  • FIGURE 8 GLP-1 AGONISTS MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
  • FIGURE 9 CAGR PROJECTIONS: GLP-1 AGONISTS MARKET, 2025-2033
  • FIGURE 10 GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES IN GLP-1 AGONISTS MARKET
  • FIGURE 11 GLP-1 AGONISTS MARKET: DATA TRIANGULATION METHODOLOGY
  • FIGURE 12 GLP-1 AGONISTS MARKET, BY PRODUCT, 2025 VS. 2033 (USD BILLION)
  • FIGURE 13 GLP-1 AGONISTS MARKET, BY ROUTE OF ADMINISTRATION, 2025 VS. 2033 (USD BILLION)
  • FIGURE 14 GLP-1 AGONISTS MARKET, BY INDICATION, 2025 VS. 2030 (USD BILLION)
  • FIGURE 15 GLP-1 AGONISTS MARKET, BY END USER, 2025 VS. 2030 (USD BILLION)
  • FIGURE 16 REGIONAL SNAPSHOT OF GLP-1 AGONISTS MARKET
  • FIGURE 17 INCREASING PREVALENCE OF TYPE-2 DIABETES AND OBESITY TO PROPEL MARKET GROWTH
  • FIGURE 18 US AND DIABETES DOMINATED NORTH AMERICAN MARKET IN 2024
  • FIGURE 19 SINGLE-DOSE FORMATS ACCOUNTED FOR LARGEST GLP-1 AGONISTS FORMAT MARKET SHARE IN 2024
  • FIGURE 20 HOME CARE SETTINGS AND FITNESS/WEIGHT MANAGEMENT FACILITIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2024
  • FIGURE 21 KINGDOM OF SAUDI ARABIA TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
  • FIGURE 22 GLP-1 AGONISTS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 23 US: PREVALENCE OF INDICATIONS THAT RESPOND TO GLP-1 DRUGS (AS OF JANUARY 2024)
  • FIGURE 24 GLP-1 AGONISTS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 25 AVERAGE SELLING PRICE TREND OF GLP-1 AGONIST PRODUCTS, BY KEY PLAYER, 2022-2024 (USD)
  • FIGURE 26 GLP-1 AGONISTS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 27 GLP-1 AGONISTS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 28 GLP-1 AGONISTS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 29 INFLUENCE OF STAKEHOLDERS IN BUYING PROCESS OF GLP-1 AGONISTS, BY TYPE
  • FIGURE 30 KEY BUYING CRITERIA FOR END USERS
  • FIGURE 31 AI USE CASES IN GLP-1 AGONISTS MARKET
  • FIGURE 32 NORTH AMERICA: GLP-1 AGONISTS MARKET SNAPSHOT
  • FIGURE 33 ASIA PACIFIC: GLP-1 AGONISTS MARKET SNAPSHOT
  • FIGURE 34 REVENUE ANALYSIS OF KEY PLAYERS IN GLP-1 AGONISTS MARKET, 2020-2024 (USD BILLION)
  • FIGURE 35 MARKET SHARE ANALYSIS OF KEY PLAYERS IN GLP-1 AGONISTS MARKET (2024)
  • FIGURE 36 GLP-1 AGONISTS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024
  • FIGURE 37 GLP-1 AGONISTS MARKET: COMPANY EVALUATION MATRIX (PLAYERS WITH PRODUCTS IN PIPELINE), 2024
  • FIGURE 38 GLP-1 AGONISTS MARKET: COMPANY FOOTPRINT (KEY PLAYERS)
  • FIGURE 39 GLP-1 AGONISTS MARKET: COMPANY FOOTPRINT (PRODUCTS IN PIPELINE)
  • FIGURE 40 GLP-1 AGONISTS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • FIGURE 41 EV/EBITDA OF KEY VENDORS
  • FIGURE 42 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 43 GLP-1 AGONISTS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS
  • FIGURE 44 NOVO NORDISK A/S: COMPANY SNAPSHOT
  • FIGURE 45 ELI LILLY AND COMPANY: COMPANY SNAPSHOT
  • FIGURE 46 SANOFI: COMPANY SNAPSHOT
  • FIGURE 47 HANSOH PHARMACEUTICAL GROUP COMPANY LIMITED: COMPANY SNAPSHOT
  • FIGURE 48 BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY SNAPSHOT
  • FIGURE 49 INNOVENT: COMPANY SNAPSHOT
  • FIGURE 50 ZEALAND PHARMA: COMPANY SNAPSHOT
  • FIGURE 51 SUN PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • FIGURE 52 AMGEN INC.: COMPANY SNAPSHOT
  • FIGURE 53 GLENMARK PHARMACEUTICALS LTD.: COMPANY SNAPSHOT
  • FIGURE 54 BIOCON: COMPANY SNAPSHOT
  • FIGURE 55 TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • FIGURE 56 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT